Afatinib is a targeted therapy that irreversibly inhibits the ErbB family of tyrosine kinases. The first-line FDA-approved indication is to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that harbors nonresistant epidermal growth factor receptor (EGFR) mutations.
Brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
Ibrutinib is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton’s tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.
Cabozantinib is a type of targeted cancer drug. It is a treatment for kidney cancer and medullary thyroid cancer that has spread to other parts of the body. Cabozantinib is a type of targeted cancer drug It is a treatment for: kidney cancer that has spread to other parts of the body (advanced kidney cancer) a type of thyroid cancer called medullary thyroid cancer that has spread to other parts of the body
Cabozantinib is a type of targeted cancer drug. It is a treatment for kidney cancer and medullary thyroid cancer that has spread to other parts of the body. Cabozantinib is a type of targeted cancer drug It is a treatment for: kidney cancer that has spread to other parts of the body (advanced kidney cancer) a type of thyroid cancer called medullary thyroid cancer that has spread to other parts of the body
Cabozantinib is a type of targeted cancer drug. It is a treatment for kidney cancer and medullary thyroid cancer that has spread to other parts of the body. Cabozantinib is a type of targeted cancer drug It is a treatment for: kidney cancer that has spread to other parts of the body (advanced kidney cancer) a type of thyroid cancer called medullary thyroid cancer that has spread to other parts of the body
Ceritinib is a type of targeted drug. It is a treatment for a type of lung cancer called non small cell lung cancer that has an enzyme called anaplastic lymphoma kinase (ALK).
Dasatinib is a prescription medicine used to treat Adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), Adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including imatinib, Adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment, Children 1 year of age and older with Ph+ CML in chronic phase, Children 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
Dasatinib is a prescription medicine used to treat Adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), Adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including imatinib, Adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment, Children 1 year of age and older with Ph+ CML in chronic phase, Children 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
Dasatinib is a prescription medicine used to treat Adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), Adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including imatinib, Adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment, Children 1 year of age and older with Ph+ CML in chronic phase, Children 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
Erlotinib is a medication used in the management and treatment of some types of non-small cell lung cancer and advanced pancreatic cancer. It is in the tyrosine kinase receptor inhibitor class of medications.
Erlotinib is a medication used in the management and treatment of some types of non-small cell lung cancer and advanced pancreatic cancer. It is in the tyrosine kinase receptor inhibitor class of medications.
Gefitinib is a type of targeted cancer drug called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that sends signals telling cancer cells to grow. Gefitinib bocks these signals. For gefitinib to work the cancer cells need to have receptors for a protein called epidermal growth factor.
Lenvatinib is a prescription medicine that is used to treat people with certain kinds of cancer. Lenvatinib is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
Lenvatinib is a prescription medicine that is used to treat people with certain kinds of cancer. Lenvatinib is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
Imatinib is a type of cancer growth blocker called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that cells use to signal to each other to grow.
Osimertinib is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):
to help prevent lung cancer from coming back after tumor(s) has been removed by surgery, or as first treatment when lung cancer has spread to other parts of the body (metastatic), or when lung cancer has spread to other parts of the body (metastatic) and have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working.
Osimertinib is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has certain abnormal epidermal growth factor receptor (EGFR) gene(s):
to help prevent lung cancer from coming back after tumor(s) has been removed by surgery, or as first treatment when lung cancer has spread to other parts of the body (metastatic), or when lung cancer has spread to other parts of the body (metastatic) and have had previous treatment with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working.
Palbociclib is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.
Regorafenib is a prescription medicine used to treat people with colon or rectal cancer that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines, a rare stomach, bowel, or esophagus cancer called GIST (gastrointestinal stromal tumor) that cannot be treated with surgery or that has spread to other parts of the body and for which they have received previous treatment with certain medicines, a type of liver cancer called hepatocellular carcinoma (HCC) in people who have been previously treated with sorafenib.
Crizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.
Sunitinib is a kinase inhibitor indicated for treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Treatment of adult patients with advanced renal cell carcinoma (RCC). Adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
Sunitinib is a kinase inhibitor indicated for treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Treatment of adult patients with advanced renal cell carcinoma (RCC). Adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
Sorafenib is a kinase inhibitor indicated for the treatment of
Unresectable hepatocellular carcinoma
Advanced renal cell carcinoma
Locally recurrent or metastatic progressive, differentiated thyroid
carcinoma (DTC) refractory to radioactive iodine treatment.
Venotoclax is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML).
Venotoclax is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML).
Venotoclax is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML).
Acalabrutinib is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
Apalutamide is a prescription medicine used to treat two types of prostate cancer:
- Metastatic castration-sensitive prostate cancer, or mCSPC,
Non-metastatic castration-resistant prostate cancer, or nmCRPC.
Erdafitinib is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery.
Erdafitinib is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery.
Erdafitinib is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery.
Neratinib is a prescription medicine used alone to treat adults with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and who have previously been treated with trastuzumab-based therapy.
Neratinib is also used with a medicine called capecitabine to treat adults with HER2-positive breast cancer that has spread to other parts of the body (metastatic) and who have received 2 or more anti-HER2 therapy medicines for metastatic breast cancer.
Lapatinib is a kinase inhibitor indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, ataxane, and trastuzumab. · letrozole for the treatment of postmenopausal women with hormone
receptor-positive metastatic breast cancer that overexpresses the HER2
receptor for whom hormonal therapy is indicated.
Lorlatinib is a prescription medicine that is used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of your body.
Larotrectinib is used to treat a certain type of solid tumors in adults, children, and infants 4 weeks of age and older that have spread to other parts of the body or cannot be treated successfully with surgery.
Nilotinib is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Nilotinib is indicated for the treatment of adult patients with CP and accelerated phase (AP) Ph+ CML resistant or intolerant to prior therapy that included imatinib.
Nilotinib is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Nilotinib is indicated for the treatment of adult patients with CP and accelerated phase (AP) Ph+ CML resistant or intolerant to prior therapy that included imatinib.
The first FDA-approved treatment for people with RET-positive advanced non-small cell lung cancer (NSCLC), thyroid cancers, and certain other cancers.
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
- Ovarian cancer,
- Breast cancer
- Pancreatic cancer
- Prostate cancer
laparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
- Ovarian cancer,
- Breast cancer
- Pancreatic cancer
- Prostate cancer
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
- Ovarian cancer,
- Breast cancer
- Pancreatic cancer
- Prostate cancer
Ruxolitinib is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Ruxolitinib is used to treat adults with certain types of myelofibrosis.
Ruxolitinib is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Ruxolitinib is used to treat adults with certain types of myelofibrosis.
Ruxolitinib is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Ruxolitinib is used to treat adults with certain types of myelofibrosis.
Entrectinib is a prescription medicine used to treat:
- Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.
A drug used to treat medullary thyroid cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body.
It is also being studied in the treatment of other types of cancer. Vandetanib blocks certain proteins, which may help keep cancer cells from growing.
A drug used to treat medullary thyroid cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body.
It is also being studied in the treatment of other types of cancer. Vandetanib blocks certain proteins, which may help keep cancer cells from growing.
Ribociclib is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic).
Niraparib is a prescription medicine used for the:
- maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Niraparib is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy